Arvinas Inc ARVN
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-09-27 |
| Shares Out. | 64,520,000 |
| Website | arvinas.com/ ↗ |
| Phone | 12035351456 |
| Employees | 246 |
| Revenue | $15.6M |
| Gross Profit | $15.6M |
| Net Income | -$57.6M |
| Free Cash Flow | -$256.9M |
| Total Assets | $647.5M |
| Total Liabilities | $260.7M |
| Equity | $386.8M |
About Arvinas Inc
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Arvinas Inc is a publicly traded company under the ticker symbol ARVN on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
24 analysts (2026-07-01)